HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for hydrochlorothiazide; quinapril hydrochloride and what is the scope of patent protection?
Hydrochlorothiazide; quinapril hydrochloride
is the generic ingredient in two branded drugs marketed by Pfizer Pharms, Apotex, Aurobindo Pharma, Chartwell Rx, Invagen Pharms, Norvium Bioscience, and Sun Pharm Inds Ltd, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.Five suppliers are listed for this compound.
Summary for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 7 |
| NDAs: | 7 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 7 |
| Patent Applications: | 1 |
| DailyMed Link: | HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| LaborMed Pharma S.A. | Phase 4 |
| Vanderbilt University Medical Center | Phase 4 |
| National Center for Research Resources (NCRR) | Phase 4 |
See all HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE clinical trials
Pharmacology for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
| Drug Class | Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
| Physiological Effect | Increased Diuresis |
Anatomical Therapeutic Chemical (ATC) Classes for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norvium Bioscience | QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 077093-002 | Mar 28, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Apotex | QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 091524-003 | Mar 12, 2013 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-002 | Dec 28, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Norvium Bioscience | QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 077093-001 | Mar 28, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-001 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-002 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-003 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | ACCURETIC | hydrochlorothiazide; quinapril hydrochloride | TABLET;ORAL | 020125-003 | Dec 28, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
